NASDAQ · QTTB
Q32 Bio Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for QTTB: Nov 12, 2026
Q32 Bio Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.36. The reported EPS for the same quarter last year was $-0.6.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.36 | $-0.32 | $-0.42 | 3 |
| Dec 2026 | $-0.31 | $-0.23 | $-0.36 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · Zacks- Fintel · Oct 12, 1:27 PM EDTLeerink Partners Initiates Coverage of Q32 Bio with OutperformFintel reports that on October 12, 2026, Leerink Partners initiated coverage of Q32 Bio (NASDAQCM:QTTB) (DB:DB0) with a Outperform recommendation.Prior to this rating action, the stock closed at $8.34 on October 9, 2026. This pre-action close represents a price change of +1.34% o
- RTTNews · Sep 30, 10:15 AM EDTQ32 Bio Sets 2027 Registration Program For Bempikibart In Alopecia(RTTNews) – Q32 Bio (QTTB) reported additional 36-week results and initial 16-week off-drug findings from Part B of the Phase 2a SIGNAL-AA trial of bempikibart in patients with severe or very severe alopecia areata.
- RTTNews · Sep 30, 10:06 AM EDTQ32 Bio Reports Bempikibart Data In Alopecia Areata(RTTNews) – Q32 Bio (QTTB) reported additional results from Part B of the Phase 2a SIGNAL-AA trial of bempikibart in patients with severe or very severe alopecia areata, presented at the EADV Congress 2026.
- Fintel · Sep 28, 10:05 PM EDTJefferies Initiates Coverage of Q32 Bio with BuyFintel reports that on September 28, 2026, Jefferies initiated coverage of Q32 Bio (NASDAQCM:QTTB) (DB:DB0) with a Buy recommendation.On the day of the rating action, September 28, 2026, the latest close for Q32 Bio was $9.23. This followed a pre-action close of $8.77 on Septembe
- RTTNews · Sep 14, 9:42 AM EDTQ32 Bio Appoints New CMO And CDO To Support Advancement Of Bempikibart(RTTNews) – Q32 Bio Inc. (QTTB) announced the appointment of José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer, strengthening the company's leadership as it prepares to advance its lead program, Bempikibart, into lat
- Zacks · Sep 7, 9:35 AM EDTDown 23.1% in 4 Weeks, Here's Why Q32 Bio (QTTB) Looks Ripe for a TurnaroundThe heavy selling pressure might have exhausted for Q32 Bio (QTTB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- Zacks · Aug 17, 9:55 AM EDTWall Street Analysts See an 182.18% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?The average of price targets set by Wall Street analysts indicates a potential upside of 182.2% in Q32 Bio (QTTB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- Zacks · Jul 31, 9:55 AM EDTWall Street Analysts Think Q32 Bio (QTTB) Could Surge 185.99%: Read This Before Placing a BetThe consensus price target hints at an 186% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- Zacks · Jul 20, 12:00 PM EDTAre You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great ChoiceDoes Q32 Bio (QTTB) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks · Jul 15, 9:55 AM EDTWall Street Analysts See an 80.12% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?The consensus price target hints at an 80.1% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- RTTNews · Jul 15, 2:27 AM EDTQ32 Bio Prices Approx.$200 Mln Offering Of Shares And Pre-Funded Warrants; Stock Up(RTTNews) – Q32 Bio Inc. (QTTB), a clinical-stage biotechnology company, priced an underwritten public offering of 6.03 million shares at a public offering price of $18.25 per share, and the offering of pre-funded warrants to certain investors to purchase 4.931 million shares at
- RTTNews · Jul 13, 10:30 PM EDTTop Biotech Gainers: QTTB Sends Strong SIGNAL; AMWL And SI In Focus(RTTNews) – Today's top biotech gainers include Q32 Bio, following positive Phase 2 results for its hair loss treatment; Agenus, as it advances development of its colon cancer drug combination, botensilimab and balstilimab; and Shoulder Innovations, which recently raised its full
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Q32 Bio Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.